Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786630 · ClinicalTrials.gov registry record · NA
Intervention to Reduce Injection Drug Use
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 726
- Enrollment target
NCT00786630: Completed NA study, sponsored by University of Colorado, Denver.
NCT00786630 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 726 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00786630, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 726 participants
- Enrollment target
Study Summary
This is a five-year prospective randomized trial comparing two intervention conditions designed to facilitate substance abuse treatment entry and enhance retention in order to reduce the behaviors associated with HIV and HCV risk among injection drug users (IDUs) and to improve client overall functioning. The overall goal of this project is to compare strengths-based case-management (CM) to an enhanced version of CM that uses case managers to facilitate a therapeutic alliance (CM/FTA) among out-of-treatment IDUs in Denver.
Interventions
- BEHAVIORAL Strengths-based case management
- BEHAVIORAL Case management plus facilitated treatment alliance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 726 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-02 |
| Phase | NA |
What the finished NCT00786630 record still lists
NCT00786630 is an interventional study that assigns participants to a tested intervention. The registered 726 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Strengths-based case management is the first listed.
NCT00786630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00786630 about?
NCT00786630 is a clinical study titled "Intervention to Reduce Injection Drug Use". This is a five-year prospective randomized trial comparing two intervention conditions designed to facilitate substance abuse treatment entry and enhance retention in order to reduce the behaviors associated with HIV and HCV risk among injection drug users (IDUs) and to improve client overall functi...
What is the current status of trial NCT00786630?
This trial is currently completed. It is a NA study. The enrollment target is 726 participants. The study started on 2007-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00786630?
The interventions under investigation include: Strengths-based case management (BEHAVIORAL), Case management plus facilitated treatment alliance (BEHAVIORAL).
Who is sponsoring clinical trial NCT00786630?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00786630's enrollment target sits among peer trials
726 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia